---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-004361"
form_type: "8-K"
ticker: "ZSQR"
cik: "0001759186"
company_name: "Z Squared Inc."
filed_at: "2024-06-20T23:59:59+00:00"
generated_at: "2026-06-01T03:36:37.496606+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Coeptis raises $4.3M in Series A Preferred financing; CEO granted 2.4M options

## Summary
- Raised $4.3M via sale of 4,300 shares of Series A Preferred at $1,000/share to accredited investors.
- Financing led by CJC Investment Trust (entity of board member Christopher Calise).
- Series A convertible at $0.40/share; automatic conversion upon $20M+ fundraising.
- CEO David Mehalick granted options for 2.4M shares (fully vested, 10-year term) on June 13.
- Investors also received 6.45% non-voting equity in new subsidiaries SNAP Biosciences and GEAR Therapeutics.

## SEC filing metadata
- accession: 0001683168-24-004361
- form_type: 8-K
- ticker: ZSQR
- cik: 0001759186
- company_name: Z Squared Inc.
- filed_at: 2024-06-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 3.02, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759186/000168316824004361/0001683168-24-004361-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759186/000168316824004361/coeptis_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-004361
- JSON: https://secwatch.observer/filing/0001683168-24-004361.json
- Plain text: https://secwatch.observer/filing/0001683168-24-004361.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.